Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 133
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | ||
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | ||
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | ||
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | ||
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | ||
| NCT01232881 | Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer | ||
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | ||
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | ||
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | ||
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | ||
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | ||
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | ||
| NCT06794229 | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis | ||
| NCT00730353 | Sutent + Taxol for Advanced Esophageal Cancer | ||
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | ||
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | ||
| NCT05583708 | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | ||
| NCT06855225 | A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma | ||
| NCT05442216 | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | ||
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | ||
| NCT00367601 | Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer | ||
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | ||
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | ||
| NCT04069273 | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma | ||
| NCT07218666 | Zanzalintinib in Men With Aggressive Variant Prostate Cancer | ||
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | ||
| NCT04364048 | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | ||
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | ||
| NCT00216099 | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer | ||
| NCT05467891 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | ||
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | ||
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | ||
| NCT03737123 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | ||
| NCT06728410 | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | ||
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | ||
| NCT00890955 | Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies | ||
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | ||
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | ||
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | ||
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | ||
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | ||
| NCT04858256 | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | ||
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | ||
| NCT03960151 | Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy | ||
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | ||
| NCT00572572 | Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors | ||
| NCT07185945 | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | ||
| NCT02500901 | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | ||
| NCT00235235 | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | ||
| NCT00234494 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer |
